Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Archive for the ‘Disease Biology’ Category

mRNA Data Survival Analysis

Posted in Artificial Intelligence - Breakthroughs in Theories and Technologies, Big Data, Bio Instrumentation in Experimental Life Sciences Research, BioIT: BioInformatics, Biological Networks, Gene Regulation and Evolution, Biomarkers & Medical Diagnostics, Biomedical Measurement Science, Cancer and Current Therapeutics, Clinical Genomics, Computational Biology/Systems and Bioinformatics, Disease Biology, Exosomes, FDA Regulatory Affairs, Gene Regulation, Genetics & Pharmaceutical, Molecular Genetics & Pharmaceutical, Pharmacogenomics, Population Health Management, Genetics & Pharmaceutical, RNA Biology, Cancer and Therapeutics, tagged Exosomes, multivariate statistical analysis, survival analysis on June 18, 2016| Leave a Comment »

mRNA Data Survival Analysis

Curators: Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

 

 

SURVIV for survival analysis of mRNA isoform variation

Shihao Shen, Yuanyuan Wang, Chengyang Wang, Ying Nian Wu & Yi Xing
Nature Communications7,Article number:11548 Feb 2016      doi:10.1038/ncomms11548

The rapid accumulation of clinical RNA-seq data sets has provided the opportunity to associate mRNA isoform variations to clinical outcomes. Here we report a statistical method SURVIV (Survival analysis of mRNA Isoform Variation), designed for identifying mRNA isoform variation associated with patient survival time. A unique feature and major strength of SURVIV is that it models the measurement uncertainty of mRNA isoform ratio in RNA-seq data. Simulation studies suggest that SURVIV outperforms the conventional Cox regression survival analysis, especially for data sets with modest sequencing depth. We applied SURVIV to TCGA RNA-seq data of invasive ductal carcinoma as well as five additional cancer types. Alternative splicing-based survival predictors consistently outperform gene expression-based survival predictors, and the integration of clinical, gene expression and alternative splicing profiles leads to the best survival prediction. We anticipate that SURVIV will have broad utilities for analysing diverse types of mRNA isoform variation in large-scale clinical RNA-seq projects.

Eukaryotic cells generate remarkable regulatory and functional complexity from a finite set of genes. Production of mRNA isoforms through alternative processing and modification of RNA is essential for generating this complexity. A prevalent mechanism for producing mRNA isoforms is the alternative splicing of precursor mRNA¹. Over 95% of the multi-exon human genes undergo alternative splicing^{2, 3}, resulting in an enormous level of plasticity in the regulation of gene function and protein diversity. In the last decade, extensive genomic and functional studies have firmly established the critical role of alternative splicing in cancer^{4, 5, 6}. Alternative splicing is involved in a full spectrum of oncogenic processes including cell proliferation, apoptosis, hypoxia, angiogenesis, immune escape and metastasis^{7, 8}. These cancer-associated alternative splicing patterns are not merely the consequences of disrupted gene regulation in cancer but in numerous instances actively contribute to cancer development and progression. For example, alternative splicing of genes encoding the Bcl-2 family of apoptosis regulators generates both anti-apoptotic and pro-apoptotic protein isoforms⁹. Alternative splicing of the pyruvate kinase M (PKM) gene has a significant impact on cancer cell metabolism and tumour growth¹⁰. A transcriptome-wide switch of the alternative splicing programme during the epithelial–mesenchymal transition plays an important role in cancer cell invasion and metastasis^{11, 12}.

RNA sequencing (RNA-seq) has become a popular and cost-effective technology to study transcriptome regulation and mRNA isoform variation^{13, 14}. As the cost of RNA-seq continues to decline, it has been widely adopted in large-scale clinical transcriptome projects, especially for profiling transcriptome changes in cancer. For example, as of April 2015 The Cancer Genome Atlas (TCGA) consortium had generated RNA-seq data on over 11,000 cancer patient specimens from 34 different cancer types. Within the TCGA data, breast invasive carcinoma (BRCA) has the largest sample size of RNA-seq data covering over 1,000 patients, and clinical information such as survival times, tumour stages and histological subtypes is available for the majority of the BRCA patients¹⁵. Moreover, the median follow-up time of BRCA patients is ~400 days, and 25% of the patients have more than 1,200 days of follow-up. Collectively, the large sample size and long follow-up time of the TCGA BRCA data set allow us to correlate genomic and transcriptomic profiles to clinical outcomes and patient survival times.

To date, systematic analyses have been performed to reveal the association between copy number variation, DNA methylation, gene expression and microRNA expression profiles with cancer patient survival^{16, 17}. By contrast, despite the importance of mRNA isoform variation and alternative splicing, there have been limited efforts in transcriptome-wide survival analysis of alternative splicing in cancer patients. Most RNA-seq studies of alternative splicing in cancer transcriptomes focus on identifying ‘cancer-specific’ alternative splicing events by comparing cancer tissues with normal controls (see refs 18, 19, 20, 21, 22, 23 for examples). A recent analysis of TCGA RNA-seq data identified 163 recurrent differential alternative splicing events between cancer and normal tissues of three cancer types, among which five were found to have suggestive survival signals for breast cancer at a nominal P-value cutoff of 0.05 (ref. 21). Some other studies reported a significant survival difference between cancer patient subgroups after stratifying patients with overall mRNA isoform expression profiles^{24, 25}. However, systematic cancer survival analyses of alternative splicing at the individual exon resolution have been lacking. Two main challenges exist for survival analyses of mRNA isoform variation and alternative splicing using RNA-seq data. The first challenge is to account for the estimation uncertainty of mRNA isoform ratios inferred from RNA-seq read counts. The statistical confidence of mRNA isoform ratio estimation depends on the RNA-seq read coverage for the events of interest, with larger read coverage leading to a more reliable estimation¹⁴. Modelling the estimation uncertainty of mRNA isoform ratio is an essential component of RNA-seq analyses of alternative splicing, as shown by various statistical algorithms developed for detecting differential alternative splicing from multi-group RNA-seq data^{14, 26, 27, 28,29}. The second challenge, which is a general issue in survival analysis, is to properly model the association of mRNA isoform ratio with survival time, while accounting for missing data in survival time because of censoring, that is, patients still alive at the end of the survival study, whose precise survival time would be uncertain. To date, no algorithm has been developed for survival analyses of mRNA isoform variation that accounts for these sources of uncertainty simultaneously.

Here we introduce SURVIV (Survival analysis of mRNA Isoform Variation), a statistical model for identifying mRNA isoform ratios associated with patient survival times in large-scale cancer RNA-seq data sets. SURVIV models the estimation uncertainty of mRNA isoform ratios in RNA-seq data and tests the survival effects of isoform variation in both censored and uncensored survival data. In simulation studies, SURVIV consistently outperforms the conventional Cox regression survival analysis that ignores the measurement uncertainty of mRNA isoform ratio. We used SURVIV to identify alternatively spliced exons whose exon-inclusion levels significantly correlated with the survival times of invasive ductal carcinoma (IDC) patients from the TCGA breast cancer cohort. Survival-associated alternative splicing events are identified in gene pathways associated with apoptosis, oxidative stress and DNA damage repair. Importantly, we show that alternative splicing-based survival predictors outperform gene expression-based survival predictors in the TCGA IDC RNA-seq data set, as well as in TCGA data of five additional cancer types. Moreover, the integration of clinical information, gene expression and alternative splicing profiles leads to the best prediction of survival time.

SURVIV statistical model

The statistical model of SURVIV assesses the association between mRNA isoform ratio and patient survival time. While the model is generic for many types of alternative isoform variation, here we use the exon-skipping type of alternative splicing to illustrate the model (Fig. 1a). For each alternative exon involved in exon-skipping, we can use the RNA-seq reads mapping to its exon-inclusion or -skipping isoform to estimate its exon-inclusion level (denoted as ψ, or PSI that is Per cent Spliced In¹⁴). A key feature of SURVIV is that it models the RNA-seq estimation uncertainty of exon-inclusion level as influenced by the sequencing coverage for the alternative splicing event of interest. This is a critical issue in accurate quantitative analyses of mRNA isoform ratio in large-scale RNA-seq data sets^{14, 26, 27, 28, 29}. Therefore, SURVIV contains two major components: the first to model the association of mRNA isoform ratio with patient survival time across all patients, and the second to model the estimation uncertainty of mRNA isoform ratio in each individual patient (Fig. 1a).

Figure 1: The statistical framework of the SURVIV model.

(a) For each patient k, the patient’s hazard rate λ_k(t) is associated with the baseline hazard rate λ₀(t) and this patient’s exon-inclusion level ψ_k. The association of exon-inclusion level with patient survival is estimated by the survival coefficient β. The exon-inclusion level ψ_k is estimated from the read counts for the exon-inclusion isoform IC_k and the exon-skipping isoform SC_k. The proportion of the inclusion and skipping reads is adjusted by a normalization function f that considers the lengths of the exon-inclusion and -skipping isoforms (see details in Results and Supplementary Methods). (b) A hypothetical example to illustrate the association of exon-inclusion level with patient survival probability over time S_k(t), with the survival coefficient β=−1 and a constant baseline hazard rate λ₀(t)=1. In this example, patients with higher exon-inclusion levels have lower hazard rates and higher survival probabilities. (c) The schematic diagram of an exon-skipping event. The exon-inclusion reads IC_k are the reads from the upstream splice junction, the alternative exon itself and the downstream splice junction. The exon-skipping reads SC_k are the reads from the skipping splice junction that directly connects the upstream exon to the downstream exon.

• Full size image (75 KB)

Briefly, for any individual exon-skipping event, the first component of SURVIV uses a proportional hazards model to establish the relationship between patient k’s exon-inclusion level ψ_k and hazard rate λ_k(t).

For each exon, the association between the exon-inclusion level and patient survival time is reflected by the survival coefficient β. A positive β means increased exon inclusion is associated with higher hazard rate and poorer survival, while a negative β means increased exon inclusion is associated with lower hazard rate and better survival. λ₀(t) is the baseline hazard rate estimated from the survival data of all patients (see Supplementary Methods for the detailed estimation procedure). A particular patient’s survival probability over time S_k(t) can be calculated from the patient-specific hazard rate λ_k(t) as . Figure 1b illustrates a simple example with a negative β=−1 and a constant baseline hazard rate λ₀(t)=1, where higher exon-inclusion levels are associated with lower hazard rates and higher survival probabilities.

The second component of SURVIV models the exon-inclusion level and its estimation uncertainty in individual patient samples. As illustrated in Fig. 1c, the exon-inclusion level ψ_k of a given exon in a particular sample can be estimated by the RNA-seq read count specific to the exon inclusion isoform (IC_k) and the exon-skipping isoform (SC_k). Other types of alternative splicing and mRNA isoform variation can be similarly modelled by this framework²⁹. Given the effective lengths (that is, the number of unique isoform-specific read positions) of the exon-inclusion isoform (l_I) and the exon-skipping isoform (l_S), the exon-inclusion level ψ_k can be estimated as . Assuming that the exon-inclusion read count IC_k follows a binomial distribution with the total read count n_k=IC_k+SC_k, we have:

The binomial distribution models the estimation uncertainty of ψ_k as influenced by the total read count n_k, in which the parameter p_k represents the proportion of reads from the exon-inclusion isoform, given the exon-inclusion level ψ_k adjusted by a length normalization function f(ψ_k) based on the effective lengths of the isoforms. The definitions of effective lengths for all basic types of alternative splicing patterns are described in ref. 29.

Distinct from conventional survival analyses in which predictors do not have estimation uncertainty, the predictors in SURVIV are exon-inclusion levels ψ_k estimated from RNA-seq count data, and the confidence of ψ_k estimate for a given exon in a particular sample depends on the RNA-seq read coverage. We use the statistical framework of survival measurement error model³⁰ to incorporate the estimation uncertainty of isoform ratio in the proportional hazards model. Using a likelihood ratio test, we test whether the exon-inclusion levels have a significant association with patient survival over the null hypothesis H₀:β=0. The false discovery rate (FDR) is estimated using the Benjamini and Hochberg approach³¹. Details of the parameter estimation and likelihood ratio test in SURVIV are described in Supplementary Methods.

 

Figure 2: Simulation studies to assess the performance of SURVIV and the importance of modelling the estimation uncertainty of mRNA isoform ratio.

We compared our SURVIV model with Cox regression using point estimates of exon-inclusion levels, which does not consider the estimation uncertainty of the mRNA isoform ratio. (a) To study the effect of RNA-seq depth, we simulated the mean total splice junction read counts equal to 5, 10, 20, 50, 80 and 100 reads. We generated two sets of simulations with and without data-censoring. For each simulation, the true-positive rate (TPR) at 5% false-positive rate is plotted. The inset figure shows the empirical distribution of the mean total splice junction read counts in the TCGA IDC RNA-seq data (x axis in the log10 scale). (b) To faithfully represent the read count distribution in a real data set, we performed another simulation with read counts directly sampled from the TCGA IDC data. Sampled read counts were then multiplied by different factors ranging from 10 to 300% to simulate data sets with different RNA-seq read depth. Continuous and dashed lines represent the performance of SURVIV and Cox regression, respectively. Red lines represent the area under curve (AUC) of the ROC curve (TPR versus false-positive rate plot). Black lines represent the TPR at 5% false-positive rate.

• Full size image (78 KB)

 

Using these simulated data, we compared SURVIV with Cox regression in two settings, without or with censoring of the survival time. In the setting without censoring, the death and survival time of each individual is known. In the setting with censoring, certain individuals are still alive at the end of the survival study. Consequently, these patients have unknown death and survival time. Here, in the simulation with censoring, we assumed that 85% of the patients were still alive at the end of the study, similar to the censoring rate of the TCGA IDC data set. In both settings and with different depths of RNA-seq coverage, SURVIV consistently outperformed Cox regression in the true-positive rate at the same false-positive rate of 5% (Fig. 2a). As expected, we observed a more significant improvement in SURVIV over Cox regression when the RNA-seq read coverage was low (Fig. 2a).

To more faithfully recapitulate the read count distribution in a real cancer RNA-seq data set, we performed another simulation study with read counts directly sampled from the TCGA IDC data. To assess the influence of RNA-seq read depth on the performance of SURVIV and Cox regression, sampled read counts were then multiplied by different factors ranging from 10 to 300% to simulate data sets with different RNA-seq read depths (Fig. 2b). The TCGA IDC data set has an average RNA-seq depth of ~60 million paired-end reads per patient. Thus, the read depth of these simulated RNA-seq data sets ranged from ~6 million reads to 180 million reads per patient, representing low-coverage RNA-seq studies designed primarily for gene expression analysis³² up to high-coverage RNA-seq studies designed primarily for alternative isoform analysis²⁹. At all levels of RNA-seq depth, SURVIV consistently outperformed Cox regression, as reflected by the area under curve of the receiver operating characteristic (ROC) curve as well as the true-positive rate at 5% false-positive rate (Fig. 2b). The improvement of SURVIV over Cox regression was particularly prominent when the read depth was low. For example, at 10% read depth, SURVIV had 7% improvement in area under curve (68% versus 61%) and 8% improvement in the true-positive rate at 5% false-positive rate (46% versus 38%). Collectively, these simulation results suggest that SURVIV achieves a higher accuracy by accounting for the estimation uncertainty of mRNA isoform ratio in RNA-seq data.

SURVIV analysis of TCGA IDC breast cancer data

To illustrate the practical utility of SURVIV, we used it to analyse the overall survival time of 682 IDC patients from the TCGA breast cancer (BRCA) RNA-seq data set (see Methods for details of the data source and processing pipeline). We chose to analyse IDC because it is the most frequent type of breast cancer³³, comprising ~70% of patients in the TCGA breast cancer data set. To control for the effects of significant clinical parameters such as tumour stage and subtype and identify alternative splicing events associated with patient outcomes across multiple molecular and clinical subtypes, we followed the procedure of Croce and colleagues in analysing mRNA and microRNA prognostic signature of IDC³³ and stratified the patients according to their clinical parameters. We then conducted SURVIV analysis in 26 clinical subgroups with at least 50 patients in each subgroup. We identified 229 exon-skipping events associated with patient survival in multiple clinical subgroups that met the criteria of SURVIV P-value≤0.01 in at least two subgroups of the same clinical parameter (cancer subtype, stage, lymph node, metastasis, tumour size, oestrogen receptor status, progesterone receptor status, HER2 status and age as shown in Fig. 3). DAVID (Database for Annotation, Visualization and Integrated Discovery) Gene Ontology analyses³⁴ of the 229 alternative splicing events suggest an enrichment of genes in cancer-related functional categories such as intracellular signalling, apoptosis, oxidative stress and response to DNA damage (Supplementary Fig. 1). Table 1 shows a few selected examples of survival-associated alternative splicing events in cancer-related genes. Using two-means clustering of each individual exon’s inclusion levels, the 682 IDC patients can be segregated into two subgroups with significantly different survival times as illustrated by the Kaplan–Meier survival plot (Fig. 4). We also carried out hierarchical clustering of IDC patients using 176 survival-associated alternative exons (P≤0.01; SURVIV analysis of all IDC patients). Using the exon-inclusion levels of these 176 exons, we clustered IDC patients into three major subgroups, with 95, 194 and 389 patients, respectively. As illustrated by the Kaplan–Meier survival plots, the three subgroups had significantly different survival times (Supplementary Fig. 2).

Figure 3: SURVIV analysis of exon-skipping events in the TCGA IDC RNA-seq data set.

IDC patients are stratified into multiple clinical subgroups based on clinical parameters including cancer subtype, stage, lymph node status, metastasis, tumour size, oestrogen receptor status, progesterone receptor status, HER2 status and age. Only clinical subgroups with at least 50 patients are included in further analyses. Numbers of patients in the subgroups are indicated next to the names of the subgroups. Shown in the heatmap are the log10 SURVIV P-values of the 229 exons associated with patient survival (P≤0.01) in at least two subgroups of the same class of clinical parameters. Turquoise colour indicates positive correlation that higher exon-inclusion levels are associated with higher survival probabilities. Magenta colour indicates negative correlation that lower exon-inclusion levels are associated with higher survival probabilities.

• Full size image (190 KB)

TABLE 1 (not shown)

Figure 4: Kaplan–Meier survival plots of IDC patients stratified by two-means clustering of the exon-inclusion levels of four survival-associated alternative splicing events.

Clustering was generated for each of the four exons separately. Black lines represent patients with high exon-inclusion levels. Red lines represent patients with low exon-inclusion levels. The P-values are from SURVIV analysis of the TCGA IDC RNA-seq data. (a) ATRIP. (b) BCL2L11. (c) CD74. (d) PCBP4.

• Full size image (107 KB)

 

Figure 5: Alternative splicing of STAT5A exon 5 is significantly associated with IDC patient survival.

(a) The gene structure of the STAT5A full-length isoform compared to the ΔEx5 isoform skipping the 5th exon. (b) Kaplan–Meier survival plot of IDC patients stratified by two-means clustering using exon-inclusion levels of STAT5A exon 5. The 420 patients in Group 1 (average exon 5 inclusion level=95%) have significantly higher survival probabilities than the 262 patients in Group 2 (average exon 5 inclusion level=85%) (SURVIV P=6.8e−4). (c) Exon 5 inclusion levels of IDC patients stratified by two-means clustering using exon 5 inclusion levels. Group 1 has 420 patients with average exon-inclusion level at 95%. Group 2 has 262 patients with average exon-inclusion level at 85%. (d) STAT5A exon 5 inclusion levels in normal breast tissues versus breast cancer tumour samples. Exon-inclusion levels are extracted from 86 TCGA breast cancer patients with matched normal and tumour samples. Normal breast tissues have average exon 5 inclusion level at 95%, compared to 91% average exon-inclusion level in tumour samples. Error bars represent 95% confidence interval of the mean.

• Full size image (64 KB)

Network of survival-associated alternative splicing events

…see http://www.nature.com/ncomms/2016/160609/ncomms11548/full/ncomms11548.html

Figure 6: Splicing factor regulatory network of survival-associated alternative splicing events in IDC.

(a–c) Kaplan–Meier survival plots of IDC patients stratified by the gene expression levels of three splicing factors: TRA2B (a, Cox regression P=1.8e−4), HNRNPH1 (b, P=3.4e−4) and SFRS3 (c, P=2.8e−3). Black lines represent patients with high gene expression levels. Red lines represent patients with low gene expression levels. (d) The exon-inclusion levels of a DHX30 alternative exon are negatively correlated with TRA2B gene expression levels (robust correlation coefficient r=−0.26, correlation P=1.2e−17). (e) The exon-inclusion levels of a MAP3K4 alternative exon are positively correlated withHNRNPH1 gene expression levels (robust correlation coefficient r=0.16, correlation P=2.6e−06). (f) A splicing co-expression network of the three splicing factors and their correlated survival-associated alternative exons. In total, 84 survival-associated alternative exons are significantly correlated with the three splicing factors. The positive/negative correlation between splicing factors and alternative exons is represented by blue/red lines, respectively. Exons whose inclusion levels are positively/negatively correlated with survival times are represented by blue/red dots, respectively. The size of the splicing factor circles is proportional to the number of correlated exons within the network.

• Full size image (140 KB)

…..

Alternative splicing predictors of cancer patient survival

see http://www.nature.com/ncomms/2016/160609/ncomms11548/full/ncomms11548.html

Figure 7: Cross-validation of different classes of IDC survival predictors measured by the C-index

A C-index of 1 indicates perfect prediction accuracy and a C-index of 0.5 indicates random guess. The plots indicate the distribution of C-indexes from 100 rounds of cross-validation. The centre value of the box plot is the median C-index from 100 rounds of cross-validation. The notch represents the 95%confidence interval of the median. The box represents the 25 and 75% quantiles. The whiskers extended out from the box represent the 5 and 95% quantiles. Two-sided Wilcoxon test was used to compare different survival predictors. The different classes of predictors are: (a) clinical information (median C-index 0.67). (b) Gene expression (median C-index 0.68). (c) Alternative splicing (median C-index 0.71). (d) Clinical information+gene expression (median C-index 0.69). (e) Clinical information+alternative splicing (median C-index 0.73). (f) Clinical information+gene expression+alternative splicing (median C-index 0.74). Note that ‘Gene’ refers to ‘Gene-level expression’ in these plots.

• Full size image (73 KB)

Next, we carried out the SURVIV analysis in five additional cancer types in TCGA, including GBM (glioblastoma multiforme), KIRC (kidney renal clear cell carcinoma), LGG (lower grade glioma), LUSC (lung squamous cell carcinoma) and OV (ovarian serous cystadenocarcinoma). As expected, the number of significant events at different FDR or P-value significance cutoffs varied across cancer types, with LGG having the strongest survival-associated alternative splicing signals with 660 significant exon-skipping events at FDR≤5% (Supplementary Data 3 and 4). Strikingly, regardless of the number of significant events, alternative splicing-based survival predictors outperformed gene expression-based survival predictors across all cancer types (Supplementary Fig. 3), consistent with our initial observation on the IDC data set.

 

Alternative processing and modification of mRNA, such as alternative splicing, allow cells to generate a large number of mRNA and protein isoforms with diverse regulatory and functional properties. The plasticity of alternative splicing is often exploited by cancer cells to produce isoform switches that promote cancer cell survival, proliferation and metastasis^{7, 8}. The widespread use of RNA-seq in cancer transcriptome studies^{15, 47, 48} has provided the opportunity to comprehensively elucidate the landscape of alternative splicing in cancer tissues. While existing studies of alternative splicing in large-scale cancer transcriptome data largely focused on the comparison of splicing patterns between cancer and normal tissues or between different subtypes of cancer^{18, 21, 49}, additional computational tools are needed to characterize the clinical relevance of alternative splicing using massive RNA-seq data sets, including the association of alternative splicing with phenotypes and patient outcomes.

We have developed SURVIV, a novel statistical model for survival analysis of alternative isoform variation using cancer RNA-seq data. SURVIV uses a survival measurement error model to simultaneously model the estimation uncertainty of mRNA isoform ratio in individual patients and the association of mRNA isoform ratio with survival time across patients. Compared with the conventional Cox regression model that uses each patient’s mRNA isoform ratio as a point estimate, SURVIV achieves a higher accuracy as indicated by simulation studies under a variety of settings. Of note, we observed a particularly marked improvement of SURVIV over Cox regression for low- and moderate-depth RNA-seq data (Fig. 2b). This has important practical value because many clinical RNA-seq data sets have large sample size but relatively modest sequencing depth.

Using the TCGA IDC breast cancer RNA-seq data of 682 patients, SURVIV identified 229 alternative splicing events associated with patient survival time, which met the criteria of SURVIVP-values≤0.01 in multiple clinical subgroups. While the statistical threshold seemed loose, several lines of evidence suggest the functional and clinical relevance of these survival-associated alternative splicing events. These alternative splicing events were frequently identified and enriched in the gene functional groups important for cancer development and progression, including apoptosis, DNA damage response and oxidative stress. While some of these events may simply reflect correlation but not causal effect on cancer patient survival, other events may play an active role in regulating cancer cell phenotypes. For example, a survival-associated alternative splicing event involving exon 5 of STAT5A is known to regulate the activity of this transcription factor with important roles in epithelial cell growth and apoptosis³⁷. Using a co-expression network analysis of splicing factor to exon correlation across all patients, we identified three splicing factors (TRA2B, HNRNPH1 and SFRS3) as potential hubs of the survival-associated alternative splicing network of IDC. The expression levels of all three splicing factors were negatively associated with patient survival times (Fig. 6a–c), and both TRA2B and HNRNPH1 were previously reported to have an impact on cancer-related molecular pathways^{40, 41, 42, 43, 44, 45}. Finally, despite the limited power in detecting individual events, we show that the survival-associated alternative splicing events can be used to construct a predictor for patient survival, with an accuracy higher than predictors based on clinical parameters or gene expression profiles (Fig. 7). This further demonstrates the potential biological relevance and clinical utility of the identified alternative splicing events.

We performed cross-validation analyses to evaluate and compare the prognostic value of alternative splicing, gene expression and clinical information for predicting patient survival, either independently or in combination. As expected, the combined use of all three types of information led to the best prediction accuracy. Because we used penalized regression to build the prediction model, combining information from multiple layers of data did not necessarily increase the number of predictors in the model. The perhaps more surprising and intriguing result is that alternative splicing-based predictors appear to outperform gene expression-based predictors when used alone and when either type of data was combined with clinical information (Fig. 7). We observed the same trend in five additional cancer types (Supplementary Fig. 3). We note that this finding was consistent with a previous report that cancer subtype classification based on splicing isoform expression performed better than gene expression-based classification²⁵. While this trend seems counterintuitive because accurate estimation of gene expression requires much lower RNA-seq depth than accurate estimation of alternative splicing²⁹, one possible explanation may be the inherent characteristic of isoform ratio data. By definition, mRNA isoform ratio is estimated as the ratio of multiple mRNA isoforms from a single gene. Therefore, mRNA isoform ratio data have a ‘built-in’ internal control that could be more robust against certain artefacts and confounding issues that influence gene expression estimates across large clinical RNA-seq data sets, such as poor sample quality and RNA degradation¹². Regardless of the reasons, our data call for further studies to fully explore the utility of mRNA isoform ratio data for various clinical research applications.

The SURVIV source code is available for download at https://github.com/Xinglab/SURVIV. SURVIV is a general statistical model for survival analysis of mRNA isoform ratio using RNA-seq data. The current statistical framework of SURVIV is applicable to RNA-seq based count data for all basic types of alternative splicing patterns involving two isoform choices from an alternatively spliced region, such as exon-skipping, alternative 5′ splice sites, alternative 3′ splice sites, mutually exclusive exons and retained introns, as well as other forms of alternative isoform variation such as RNA editing. With the rapid accumulation of clinical RNA-seq data sets, SURVIV will be a useful tool for elucidating the clinical relevance and potential functional significance of alternative isoform variation in cancer and other diseases.

 

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading...

Read Full Post »

« Newer Posts - Older Posts »

• Follow Blog via Email

  Enter your email address to follow this blog and receive notifications of new posts by email.

  Email Address

  Follow

  Join 2,056 other subscribers

• Recent Posts

  • Grok thinks like PhDs – Hybrid Model for Autonomous Update of Doctoral Dissertations with Original PhD Student Author editing and acceptance of Grok’s updated output. 3rd Joint article, a pilot study for Validation of an Autonomous Journal Articles Updating System (AJAUS) tested on Autonomous Update of Aviva Lev-Ari, PhD, RN Doctoral Thesis, UC, Berkeley, 1983. January 31, 2026
  • 2026 World Economic Forum, 1/19 – 1/23/2026, Davos, Switzerland, LPBI Group’s KOLs interpretation of AI in Health Videos January 24, 2026
  • Evolving LPBI Group’s Portfolio of Intellectual Properties (IP): From 2021 Vision to 2026 Reality January 12, 2026
  • Aviva Lev-Ari, PhD, RN – Biography ->> Grokepedia Entry January 11, 2026
  • List of Articles included in the Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter January 10, 2026
  • Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter January 10, 2026
  • Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com January 10, 2026
  • The youngest leader in AI in Health: Tanishq Mathew Abraham, Ph.D. (@iScienceLuvr) January 8, 2026
  • 2026 Grok Multimodal Causal Reasoning on Proprietary Cariovascular Corpus: From 2021 Wolfram NLP Baseline to Thousands of Novel Relationships – A Second Head-to-Head Validation of LPBI’s Domain-Aware Training Advantage January 6, 2026
  • Workflow for Dynamic Linkage and Transition between two Authoring Systems: LPBI Group’s WordPress.com Multi-Authors Authoring System and Microsoft PowerPoint product for Slide show presentation – Part 10.1 in Composition of Methods January 6, 2026

• Archives

  Archives Select Month January 2026  (10) December 2025  (8) November 2025  (8) October 2025  (12) September 2025  (2) July 2025  (4) June 2025  (8) May 2025  (4) April 2025  (2) March 2025  (1) February 2025  (2) January 2025  (3) December 2024  (1) November 2024  (5) October 2024  (7) September 2024  (7) August 2024  (1) June 2024  (1) May 2024  (2) April 2024  (2) January 2024  (1) November 2023  (1) October 2023  (3) September 2023  (3) August 2023  (2) July 2023  (2) June 2023  (7) May 2023  (4) April 2023  (2) March 2023  (5) February 2023  (2) January 2023  (3) December 2022  (2) October 2022  (6) September 2022  (2) August 2022  (1) July 2022  (3) June 2022  (3) May 2022  (8) April 2022  (10) March 2022  (7) February 2022  (7) January 2022  (3) December 2021  (3) November 2021  (4) October 2021  (11) September 2021  (5) August 2021  (8) July 2021  (21) June 2021  (8) May 2021  (10) April 2021  (8) March 2021  (15) February 2021  (17) January 2021  (20) December 2020  (10) November 2020  (12) October 2020  (26) September 2020  (17) August 2020  (22) July 2020  (27) June 2020  (33) May 2020  (26) April 2020  (42) March 2020  (22) February 2020  (11) January 2020  (7) December 2019  (20) November 2019  (13) October 2019  (11) September 2019  (3) August 2019  (8) July 2019  (25) June 2019  (47) May 2019  (40) April 2019  (27) March 2019  (29) February 2019  (17) January 2019  (50) December 2018  (14) November 2018  (17) October 2018  (18) September 2018  (17) August 2018  (8) July 2018  (20) June 2018  (22) May 2018  (17) April 2018  (12) March 2018  (20) February 2018  (26) January 2018  (16) December 2017  (6) November 2017  (20) October 2017  (13) September 2017  (16) August 2017  (16) July 2017  (19) June 2017  (20) May 2017  (32) April 2017  (21) March 2017  (10) February 2017  (24) January 2017  (21) December 2016  (43) November 2016  (8) October 2016  (40) September 2016  (67) August 2016  (59) July 2016  (75) June 2016  (37) May 2016  (95) April 2016  (152) March 2016  (175) February 2016  (196) January 2016  (139) December 2015  (90) November 2015  (287) October 2015  (237) September 2015  (115) August 2015  (96) July 2015  (63) June 2015  (44) May 2015  (53) April 2015  (76) March 2015  (95) February 2015  (83) January 2015  (75) December 2014  (75) November 2014  (88) October 2014  (135) September 2014  (117) August 2014  (88) July 2014  (88) June 2014  (109) May 2014  (60) April 2014  (85) March 2014  (58) February 2014  (72) January 2014  (107) December 2013  (104) November 2013  (136) October 2013  (62) September 2013  (32) August 2013  (46) July 2013  (74) June 2013  (110) May 2013  (112) April 2013  (86) March 2013  (92) February 2013  (63) January 2013  (63) December 2012  (46) November 2012  (71) October 2012  (84) September 2012  (82) August 2012  (122) July 2012  (59) June 2012  (34) May 2012  (46) April 2012  (2)

• Categories

  Categories Select Category 3D Printing for Medical Application  (239)    3D Plotting Scaffolds  (44)    BioInks  (34)       Biopolymer Blend Open Porous  (18)       Dental Applications  (10)    BioPrinting in Regenerative Medicine  (77)       Cell Level  (16)       MicroEngineering Cell-Tissue & Systems  (31)       Tissue Engineering  (37)    Cardiovascular and Vascular Systems  (30)       Artificial Vascular Structures  (9)       Cardiovascular Tissue  (8)    Drug Development using MultiOrgan Chip  (11)    Drug Development/Formulation using 3D Printing  (10)    MEMS  (16)       Bio-MEMS  (12)    Organ-on-a-Chip  (11)    Programmable Sensors (Carbon Nano Tubes)  (5) 3rd Party IP: Drug DIscovery  (1) 4D Printing and Meta Materials  (10) Academic Publishing  (223)    Key Opinion Leaders in eScientific Publishing – Interviews with  (8) Advanced Drug Manufacturing Technology  (96)    Antimalarial Preparation  (8)    Autologous Cell Therapy  (14)    Automated Cell Processing  (13) Allergy and Infectious Diseases  (12) Alzheimer’s Disease  (163)    Etiology  (77)    Medical Device Therapies for Altzheimer’s Disease  (15)    Pharmacotherapy and Cell Activity  (51) Anticancer Resistance  (31) Art Exhibits on the Human Condition  (1) Art Inspires Science  (4) Article Type  (2)    Authored  (1)    Curated  (2)    Scientific report  (1) Artificial Heart  (2) Artificial Intelligence – General  (232)    An executive’s guide to AI  (10)    Artificial Intelligence – Breakthroughs in Theories and Technologies  (115)    Artificial Intelligence Applications in Health Care  (125)       Artificial Intelligence in CANCER  (39)       Artificial Intelligence in Health Care – Tools & Innovations  (74)    Artificial Intelligence in Medicine – Application for Diagnosis  (69)       Artificial intelligence applications for cardiology  (31)          AI-assisted Cardiac MRI  (10)       Artificial Intelligence in Psychiatry  (6)       Deep Learning in Pathology  (18)    Artificial Intelligence in Medicine – Applications in Therapeutics  (64)    ChatGPT, GPT-4  (7)       ChatGPT at LPBI Group  (3)       ChatGPT in Academic Education  (3)    Machine Learning  (71)       Deep Learning  (25)       Natural Language Processing (NLP)  (45)    Machine learning in predicting type 2 diabetes  (5) Auditory and vision  (13) Autism Spectrum Disorders  (10) Autoimmune Inflammatory DIseases  (24)    Crohn’s disease  (5)    Tolerance-inducing Autoimmune Disease Therapeutics  (6)    Ulcerative Colitis  (3) Autophagosome  (4) Bacterial Resistance  (25) Behavior  (26) Behavioral Genetics  (21) Big Data  (88)    Intelligent Information Systems  (51) Bio Instrumentation in Experimental Life Sciences Research  (368)    Analytical Instruments Industry  (5)    Microfuidics  (8) Bio-Ethics  (15) BioBanking  (36) Biodegradable Drug-eluting Material  (8) Bioengineering & reverse engineering design  (43) BioIT: BioInformatics  (147) BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics  (135)    Advanced Computing Platform  (32)       Blockchain Transactions System  (6)          Platform for Content Monetization embedded Content Promotion  (1)    Pancreatic adenocarcinoma classifier  (4)    Simulation Modeling in NGS  (5) Biological Engineering  (43) Biological Networks  (193) Biological Networks, Gene Regulation and Evolution  (479)    Virology  (10) Biomarkers & Medical Diagnostics  (571)    VOC – Volatile Organic Compounds as BioMarkers  (2) Biomedical Measurement Science  (173) BioSimilars  (112) BioTechnology – Venture Creation  (131)    Foundations for supporting Science and Education  (14)    Philanthropy to Academic Institution  (3) BioTechnology – Venture Creation, Venture Capital  (108)    Seeking Talent  (3) BiVAD  (1) Blindness  (6) Bone Disease and Musculoskeletal Disease  (82) Brain Basis of Emotion  (5) Business Career Consideration  (1) Ca2+ triggered activation  (61) Calcium  (21) Calcium Signaling  (71) Calmodulin Kinase and Contraction  (36) Cancer – General  (186) Cancer and Current Therapeutics  (411)    interventional oncology  (49)       Breast Cancer – impalpable breast lesions  (20)       Prostate Cancer: Monitoring vs Treatment  (9) CANCER BIOLOGY & Innovations in Cancer Therapy  (1,122)    Anaerobic Glycolysis  (51)    Cachexia  (18)    Cancer Genomics  (84)       Circulating Tumor Cells (CTC)  (27)          Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood  (17)             mRNA  (6)          MagSifter chip  (1)       KRAS Mutation  (9)       Li-fraumeni syndrome.  (3)       TP53 – Germline mutations  (8)    cancer metabolism  (28)    Funding Opportunities for Cancer Research  (12)    Genomic Expression  (150)    Glioblastoma  (7)    Hexokinase  (14)    Loss of function gene  (18)    Metabolic Immuno-Oncology  (21)    Metastasis Process  (15)    Methylation  (33)    Microbiome and Responses to Cancer Therapy  (10)    Monoclonal Immunotherapy  (29)    mtDNA  (13)    Oxidative phosphorylation  (56)    Pancreatic cancer  (10)    Pyruvate Kinase  (27)    The NCI Formulary  (1)    tumor microenvironment  (16)    Warburg effect  (50) Cancer Informatics  (104) Cancer Prevention: Research & Programs  (131) Cancer Screening  (108) Cancer Vaccines: Targeting Cancer Genes for Immunotherapy  (30)    Engineering Enhanced Cancer Vaccines  (3) cancer-general  (6) Cardiac and Cardiovascular Surgical Procedures  (328)    Aortic Valve: TAVR, TAVI vs Open Heart Surgery  (91)       Prosthesis-Patient Mismatch (PPM) in TAVI vs SAVR  (2)       TAVI vs Open Heart Surgery  (6)       Transcatheter Aortic Valve Replacement via the Transcarotid Access  (3)       Transcaval TAVR Procedure  (3)       Valve-in-Valve Procedure  (5)    Atrial Fibrilation (a-Fib), Cardiac Pacing and Arrhythmias  (18)    BackBeat’s Cardiac Neuromodulation Therapy (CNT) bioelectronic therapy  (1)    CABG  (47)    Cancer Surgery of the Heart  (10)    Cardiovascular Fluid Management: algorithms  (1)    Heart Transplant  (16)    Heart-Lung Transplant  (11)    Implantation  (3)    Left Main Coronary Artery Disease (LMCAD)  (3)    Mechanical Assist Devices: LVAD, RVAD, BiVAD, Artificial Heart  (22)    Mitral Valve: Repair and Replacement  (64)       TMVR – Transcatheter Mitral Valve Repair  (5)    PCI  (108)       Bioresorbable Vascular Scaffold (BVS)  (4)       Invasive FFR for PCI  (2)       Multivessel PCI FFR Guidance  (1)       Robotic-assisted percutaneous coronary intervention  (2)       Stent Retriever in endovascular thrombectomy  (3)    Peripheral Arterial Disease & Peripheral Vascular Surgery  (65)       Abdominal Aorta  (20)       Carotid Artery  (15)       Limb ischemia  (4)       Thoracic Aorta  (16)    Pulmonary Valve Replacement and Repair  (3)    Renal Denervation  (20)    Replacement  (1)    Robotically assisted Cardiothoracic Surgery  (2)    Tricuspid Valve Repair  (7)    Vena Caval Filters: Device for Prevention of Pulmonary Embolism and Thrombosis  (2) Cardiovascular Pharmacogenomics  (171) Cargo  (3) Cell Biology  (323) Cell Biology, Signaling & Cell Circuits  (672)    Apoptosis  (17)    Autophagy-Modulating Proteins  (6)    “Antibody–enzyme conjugates”  (6)    Cell Processing System in Cell Therapy Process Development  (27)    Endoplasmic reticulum  (3)    Enzymatic mechanism underlying the synthesis of adenosine triphosphate (ATP)  (3)    Ubiquitin  (11) Cerebrovascular and Neurodegenerative Diseases  (123)    Stroke  (9) Chemical Biology and its relations to Metabolic Disease  (464)    #BIGAxisSummit  (1)    Gut Microbiome and Obesity  (8) Chemical Genetics  (350) Child and Adolescent Psychiatry  (13) Childhood cancer  (17) Childhood malnutrition  (3) children  (3) Circulating Progenitor Cells  (27)    Bone marrow derived cells  (17)    Endothelial cells  (7)    Umbilical cord cells  (6) Clinical & Translational  (238) Clinical Diagnostics  (220)    Mass automation of plasma proteins  (13) Clinical Genomics  (144) Coagulation Therapy and Internal Bleeding  (83) Cognition  (47) Commercialization  (20) Components and IRB related issues  (4) Computational Biology/Systems and Bioinformatics  (470)    Computational Histopathology  (3)    Meta-analysis of transcriptome data  (10) Conference Coverage with Social Media  (494)    MassBio  (3) coronavirus  (18) COVID-19  (20) CRISPR/Cas9 & Gene Editing  (192)    CRISPR alternative for editing genes without cutting  (14)       CAST – Alternative to CRISPR/Cas9  (3)       Transposon-encoded CRISPR–Cas systems direct RNA-guided DNA integration  (4)    CRISPR applied to Human Germ Line  (13)       Gene Editing Impact on Longevity  (6) CT  (20) Cytokines  (20) Cytoskeleton  (85) Developmental biology  (107) Diabetes Mellitus  (146)    Artificial Pancreas for Type 2 Diabetes  (4)    Artificial Pancreas for Type1 Diabetes  (8)    Gestational diabetes  (5) Diagnostic Immunology  (61) Diagnostics and Lab Tests  (128)    Liquid Biopsy: Circulating Tumor Cells in Urine and Blood  (9) Digital HealthCare – biotech & internet joint ventures  (47) Disease Biology  (334) Disease Biology, Small Molecules in Development of Therapeutic Drugs  (487) DNA repair  (73)    Apoptosis  (13)    Autophagy  (13)    Cell death pathways  (19)    Proteolysis  (8)    Proteosome  (8) Drug Delivery Platform Technology  (157)    Drug Carrier Design  (21)       Medication Remote Compliance Monitoring  (3)    Exosomes: Natural Carriers for siRNA Delivery  (9) Drug Toxicity  (74) Ecosystems & Industrial Concentration in the Medical Device Sector  (172)    Cardiac & Vascular Repair Tools Subsegment  (128)    Exec Compensation in the Cardiac & Vascular Repair Tools Subsegment  (14)    Massachusetts Niche Suppliers and National Leaders  (20) Electronic Health Record  (10) Embryology  (24) Empathy  (6) Endocrine Diseases  (60) Enzyme Induction  (46)    ion-transporting enzyme  (2)    K + -ATPase.  (1)    Na +  (2) Epigenetics and Environmental Factors  (35) Ethics and Leadership  (10) Executive Compensation – Big Pharma  (3) Fat soluble vitamins  (4) FDA  (71) FDA Regulatory Affairs  (358)    FDA, CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP, GLP, ISO 14155  (52)    ISO 10993 for Product Registration: FDA & CE Mark for Development of Medical Devices and Diagnostics  (30) Fetal Ultrasound  (2) Fiction and medicine  (5) Frontiers in Cardiology and Cardiovascular Disorders  (929)    Acute Myocardial Infarction  (63)       Cardiogenic Shock  (5)    Anemia in CVD Patients  (6)    Cardio-Oncology  (4)    Cardiomyopathy  (57)    Cardiovascular Research  (187)       Myocardial metabolism, Myocardial ischemia, myocardial perfusion, Myocardial adenine nucleotide metabolism  (64)       Pre-Clinical Animal Model Development  (23)    Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Pulmonary Arterial Hypertension (PAH)  (20)    Cost of Inpatient Stay for Cardiovascular Diagnosis for Admission  (1)    Electrophysiology  (111)       Ablation Procedure vs Drug Therapy  (2)       Arrhythmia Detection with Machine Learning Algorithms  (7)       Cardiotoxic Risks of Immune Checkpoint Inhibitors  (1)       Genomic Analysis of EKG Electrophysiology Genomics  (3)       implantable cardioverter defibrillator (ICD) and External Defibrillation  (1)       implantable pacemaker  (2)       Rare heart rhythm disorders and Long QT syndrome (LQTS)  (7)    Epigenetics and Cardiovascular Risks  (57)    Heart Failure (HF)  (51)       Acute coronary syndrome  (7)       congestive heart failure  (19)       Hypertensive Disorders of Pregnancy  (1)    Medical Devices R&D and Inventions  (212)       Assist Devices: LV  (3)       RV  (1)       Stents & Tools  (90)       Valves & Tools  (67)    Origins of Cardiovascular Disease  (422)       Atherogenic Processes & Pathology  (180)       Congenital Heart Disease  (34)          Genetic Mutations in Congenital Heart Disease  (4)       inflammation independent of lipid levels  (13)       Systemic Inflammatory Diseases as CVD Risk  (12)    Pharmacotherapy of Cardiovascular Disease  (356)       HTN  (176)       HTN in Youth  (8)       Resident-cell-based  (43)       Subarachnoid Hemorrhage (SAH)  (1)       Transthyretin amyloid cardiomyopathy (ATTR-CM)  (1)    Spontaneous Coronary Artery Dissection (SCAD)  (6)    Stroke  (15)       endovascular thrombectomy  (6)    Vascular Diseases  (21)       mesenteric ischemia  (3) Future Pandemics Inform-graphics  (1) Gastroenterology  (38) Gene Regulation  (232) Gene Regulation and Evolution  (137) Genetics & Innovations in Treatment  (176) Genetics & Pharmaceutical  (203) Genome Biology  (967)    Exosomes  (25)    Gene Therapy & Gene Editing Development  (42)    mRNA Therapeutics  (20)    Mutagenesis  (27)    Single Cell Genomics  (25)    Single-cell sequencing  (20)    Variation in human protein-coding regions  (35) Genomic Endocrinology  (42) Genomic Testing: Methodology for Diagnosis  (416) Genomics Pharmacy  (40) Global Market of Medical Devices Technology  (2) Global Medical Publishers by Country  (3) Global Partnering & Biotech Investment  (47) GLP  (4) Glycobiology: Biopharmaceutical Production  (16) Glycobiology: Biopharmaceutical Production, Pharmacodynamics and Pharmacokinetics  (28) Health Care System by Country  (58)    AI Models in Healthcare  (12)    Centers for Medicare & Medicaid Services  (8)    Health in Israel  (2)    India  (1)    United States  (27)       Hospital-based Medical Innovations  (10)       Medical Recertification and Maintenance of Certification (MOC)  (1) Health Economics and Outcomes Research  (384)    Women Health  (18)       Heart and Brain Disease in Women  (3) Health Law & Patient Safety  (165)    and Bioethics  (14)    Biotechnology  (12)    Health Law Policy  (13) HealthCare IT  (138) Healthcare Reform  (117)    Accountable Care Organizations  (26)    Affordable Care Act  (29)       Repair  (1)       Repeal ACA  (1)       Replace  (1)    Federal Budget Appropriations  (26)    Healthcare costs and reimbursement  (59)    Indigent Nutrition  (14)    Medicare and Medicaid  (20)    Prescription Drugs Costs  (21)    Skilled Nursing Facilities  (6)    Technology Capital Expenses  (15)    Uninsured and Underinsured  (20) Hematology  (100)    Acute lymphocytic leukemia  (18)    Acute myelocytic leukemia  (21)    Hematopoiesis  (48)    Lymphoma  (21) History and physical exam  (6) Human aging  (27) Human Immune System in Health and in Disease  (246) Human Sensation and Cellular Transduction: Physiology and Therapeutics  (21) Image Processing/Computing  (41) Imaging-based Cancer Patient Management  (116) Immuno-Oncology & Genomics  (133)    mRNA platform in Drug DIscovery  (6) Immunodiagnostics  (139)    Cancer-Immune Interactions  (29)    CNS-Immune Interface  (5)    Neuronal Circuits  (4) Immunology  (123)    Adaptive Immune Response to Biomaterials and Tissue Repair  (13)    Antibody Responses Predict Antigen Exposure  (17)    Cytokine Receptor Structure  (8)    Human Antibody Response  (18)    Human Circulating Antibody Repertoire  (11)    Human Naive B Cell Repertoire  (8)    MHC Repertoires for Antigen Prediction  (8)    Protection Against Autoimmune Disease  (11)    Synthetic Immunology: Hacking Immune Cells  (15) Immunotherapy  (133)    CAR-T  (14)    combination immunotherapies.  (14)    Efficacy of Anti-Tumor T Cells  (13)    Engineering Better T Cells  (8)    Immune Engineering  (17)    Immune Modulatory  (15)    Integrin-targeted Combination Immunotherapy  (6)    Modulating Macrophages in Cancer Immunotherapy  (16)    NK Cell-Based Cancer Immunotherapy  (19)    Synergistic Innate and Adaptive Immunotherapy  (14) Income Disparity  (2) Infectious Disease & New Antibiotic Targets  (162)    Antibiotic resistance  (7)    Viral diseases  (37)       Myocarditis  (1) Infectious Disease Immunodiagnostics  (58)    Virology – Vector-borne DIsease  (17) Inflammasome  (29)    Anti-tumor necrosis factor drugs (TNF inhibitors)  (3) Innovation in Immunology Diagnostics  (111)    Universal Immune Cell Therapies (uICT)  (11) Innovations  (186)    R&D Expenditure  (8) Innovations in Neurophysiology & Neuropsychology  (145)    Age and Life Expectancy  (3)    autism spectrum disorder  (1)    Circadian Rhythm and Sleep  (6)    hNPCs  (1)    Nervous System Function  (2)    Relapsing Multiple Sclerosis  (1) Intellectual Property  (83)    Disputes and Settlements  (9)    IP Valuation Models – Pricing Intangible Assets  (7)    Patent Law in Biotech  (12) Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough  (119) International Global Work in Pharmaceutical  (190) Interventional Oncology: Radiofrequency Ablation, Transarterial Chemoembolization, Microwave Ablation and Irreversible Electroporation (IRE)  (12) Interviews with Scientific Leaders  (315)    Albany Medical Center Prize in Medicine and Biomedical Research  (2)    Annual Breakthrough Prize  (4)    Annual Lewis S. Rosenstiel Award  (2)    Awards in Cardiology and Cardiovascular Medicine  (6)    CEOs of Biotech Companies  (3)    Gerald D Aurbach Award for Outstanding Translational Research  (2)    Interviews with Key Opinion Leaders (KOLs)  (10)    James Prize in Science and Technology Integration  (2)    Jessie Stevenson Kovalenko Medal – Medical Sciences  (2)    Lemelson-MIT Prize  (2)    Life Sciences Breakthrough Prize  (5)    Mosteller Statistician of the Year Award  (2)    Mourning the Loss of a Scientific Leader  (3)    National Academy of Sciences AWARDS  (4)    Nobel Prize Winners  (29)    Noble Prize (Not Nobel Prize)  (2)    Paul Marks Prize for Cancer Research  (2)    Russ Prize recognizes bioengineering achievements worldwide  (2)    The Dan David Prize  (6)    Warren Alpert Foundation Prize Recipients  (4)    Wolf Prize  (2)    Wolf Prize in Medicine  (2)    women in science  (5) Investment in Technological Breakthrough  (60) Ionic Transporters Na+  (25) IP Development by LPBI Group Team  (14) IP Development by LPBI Group Team & Other Organizations  (8) ISO 14155  (3) Joint Venture – SBH & M3DP: SOP and Arrangements  (1) Justice & Law  (1) K  (15) Lab-on-a-chip  (2) Landscape  (1) Lasers and photonics  (18)    Midrange IR spectroscopy  (1) Law and Medicine Conflicts  (14) Leadership, Power, Social Interlocking Connections  (13) Lipid metabolism  (109)    Fatty acids  (38)    Lipids  (38)    PCSK9 Inhibitor Therapy  (19) Lipidomics  (11) Liposome  (4) Liver & Digestive Diseases Research  (122) LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management  (143)    Award Nominations  (5)    BioMed e-Books e-Series by LPBI Group  (9)    Feedback from Investors: LPBI Portfolio of Five Businesses  (2)    LPBI Group Founder – Aviva Lev-Ari  (27)    PhD  (1)    RN  (1) LPBI Management  (23) Massachusetts Academy of Sciences (MAS)    (2) Materials Science & Engineering  (37)    Organic BioElectronics  (2) Math  (13)    Great Discoveries  (7) Mechanical Assist Devices: LVAD  (4) Medical and Population Genetics  (193) Medical Devices R&D Investment  (242)    21st Century Cures Act  (2)    CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP  (14)    Rhythm management device hardware: dual-chamber pacemakers  (1)       Systolic HTN  (1) Medical Imaging Technology  (59) Medical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound  (164)    Circumferential-Intravascular-Radioluminescence-Photoacoustic-Imaging (CIRPI)  (3)    Echocardiography  (3)    MRI  (18)    Noninvasive Diagnostic Fractional Flow Reserve (FFR) CT  (6)    Ultra Sound  (10) Melatonin & Circadian Regulation  (9) memory loss  (1) Metabolism  (239)    Biochemical pathways  (144)       Enzymes and isoenzymes  (73)          Dehydrogenase  (16)          Kinase  (28)          Phosphatase  (9)          Phosphorylase  (22)          tyrosine decarboxylases  (3)    Inosine nucleotides  (9)    Leloir pathway  (6)    microbiome  (7)    Pentose monophosphate shunt  (14)    Pyridine nucleotides  (28)       Pyridine nucleotide transhydrogenase  (7) Metabolomics  (321) Methods  (37) Mg++  (10) Microbiologial genetics  (36) Microbiology  (68)    Virology  (14) Micronutrients  (16) Microvesicle  (7) Microwave Ablation and Irreversible Electroporation (IRE)  (1) Mobile Healthcare  (5) Molecular Genetics & Pharmaceutical  (377)    Organoids  (3) Monoclonal antibody therapy  (14) Mutant Gene Expression  (42) Myocardial adenine nucleotide metabolism  (6) Myocardial Ischemia  (26) Myocardial Metabolism  (36) Na-K transport  (40) Na-K-ATPase  (27) Nanotechnology for Drug Delivery  (99) Nephrology  (46) Nephrology & Regenerative medicine  (9) Neurodegenerative Diseases  (89)    hNPCs  (3)    MS  (5) Neurohumoral Transmission  (68)    Ca2+ triggered activation  (21)    Calmodulin  (13)    Parkinson’s disease dyskinesia levodopa  (3)    PKC  (13)    Synaptic vesicle  (20) Neurological Diseases  (121) Neuroscience  (126) Next Generation Sequencing (NGS)  (27)    Nanopore sequencing  (1) NIH Common Fund  (1) Nitric Oxide in Health and Disease  (136) Nuclear Medicine  (11) Nutrigenomics  (68) Nutrition  (195)    Nutritional Supplements: Atherogenesis, lipid metabolism  (50) Nutrition and Phytochemistry  (62)    Minerals in Medicine  (4)    Plant extract  (22) Nutrition Disorders  (31) Nutritional Supplements: Atherogenesis  (31) Obesity  (19) Oligonucleotide Therapeutics & Delivery  (7) Oncolytic virus & OncoViro-Therapy  (22)    Synthetic Virology  (1) Organ-on-a-Chip & 3D Printing in Life Sciences  (7) Pain: Etiology, Genetics & Innovations in Treatment  (24) Parasitology  (5)    Malaria  (4)    Tropical diseases  (1) Patents  (34) Patient Experience  (66)    Art therapy  (1)    Hospital reputation  (7)    Humor  (1)    Music therapy  (2)    Pain Alleviation  (7)    Patient Outlook  (28)    Reputation of Interventionist  (4)    Support Staff  (13)    Supportive therapies  (6)       laughfter  (1)    Surgical Procedure  (9) Patient Experience: Personal Memories of Invasive Medical Intervantion  (30) Patient’s Voice: Personal Experience with Invasive Medical Procedures  (18) Perioperative Statins at Noncardiac Surgery  (2) Personal Health Applications: Tech Innovations serves HealhCare  (43) Personalized and Precision Medicine & Genomic Research  (736)    Longevity  (3)    New Drug Approval  (5)    Patient-centered Medicine  (39)       cell-based therapy  (9)       stem cell biology and patient-specific  (7)    Personalized Medicine Coalition  (10)    Precision Cancer Medicine  (31) Phagophore  (2) Pharmaceutical Analytics  (261)    Pharmacologic toxicities  (62) Pharmaceutical Discovery  (109)    Rapid automation of plasma protein pools  (17) Pharmaceutical Drug Discovery  (200)    Drug Development Process  (55)       Drug Discovery Chemistry  (29)    drug repurposing  (10) Pharmaceutical Industry Competitive Intelligence  (343)    Pharmacovigilance  (7)    Value-based Drug Pricing  (8) Pharmaceutical R&D Informatics  (44) Pharmaceutical R&D Investment  (299) Pharmacodynamics and Pharmacokinetics  (24) Pharmacogenomics  (159) Photography Collection  (1) Physics  (12) Placenta  (7) Population genetics  (27) Population Health Management  (204)    Evolution of Biology Through Culture  (14)    U.S. Employment-to-Population Ratio  (8) Population Health Management, Genetics & Pharmaceutical  (643)    COVID-19  (157)       Biomarkers: Inflammation  (37)       Cancer Researchers Fighting COVID-19  (14)       COVID-19 effects on Human Heart  (15)       COVID-19: Pandemic Surgery Guidance  (19)       Economic Impact of Coronavirus Pandemic  (41)       number of asymptomatic infections  (27)       Treatment Protocols for COVID-19  (62)    SARS-CoV-2  (141)       Coronavirus Gene Expression  (66)          SARS-CoV-2 circulating variants   (14)          SARS-CoV-2 Viral Variants  (19)       Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis  (2)       Immune-Mediation (independent immunopathology: lung and reticuloendothelial system)  (30)       Mechanisms of infection by SARS-CoV-2  (21)       SAR-Cov-2 a vasculotropic (blood vessels) RNA Virus  (35)          SARS-COV2 Hijacking the Complement and Coagulation Systems  (19)       Seasonality & Environmental Factors in Resurgence  (26)       Serology tests for coronavirus antibodies  (44)       T-cell response to SARS-CoV-2 infection  (14)       Vaccinology  (51)          Mechanism of Thrombosis with AZ & J&J COVID-19 Vaccines  (5)       Virtual Drug Molecule Screening targeting SAR-CoV-2 proteins  (8)    Virus Infective Acute Respiratory Syndrome: SARS-CoV  (92) Population Health Management, Nutrition and Phytochemistry  (162) Preimplantation Genetic Diagnosis and Reproductive Genomics  (13) Protein-energy malnutrition  (12) Proteomics  (367)    Amino acids  (54)    Proteins  (138) Pulmonary diseases  (16)    Lung and pulmonology  (15) Pulmonary pathology  (8) Radio Frequency (RF)-based Surgical Solutions  (2) REAL TIME Conference Coverage Twitter’s Hashtags and Handles per Presentation/session  (50) Regenerative Biology and Medicine  (92) Regulated Clinical Trials: Design, Methods, Components and IRB related issues  (265) Reproductive Andrology, Embryology, Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics  (113) Reproductive Biology & Bio Instrumentation  (78) RNA Biology  (81)    RNA interference (RNAi) therapeutic  (4) RNA Biology, Cancer and Therapeutics  (64) RVAD  (1) SBIR, SBA, NIH, NSF  (3) Schizophrenia  (16) Scientific & Biotech Conferences: Press Coverage  (182) Scientific Publishing  (609)    Curation  (585)       Curation methodology  (40)       De novo synthesis  (16)       Dialectic  (17)       Discovery process  (72)       Evolutionary cognition  (52)       Experimental validation  (91)       Explanatory  (91)       Historical relevance  (71)       Technology Advance Assessment of  (69)       Theoretic convergence  (27)    Open Access Journals  (37) Scientist: Career considerations  (197)    Big Data & Analytics  (17)    Data Science  (13)    Women in Life Sciences  (12) Scoop.it  (19) Sensors & Analytics  (18) Sepsis  (2) Severe Autism  (3) Signaling  (102)    Phosphorylation  (43)    S-nitrosylation  (13)    Ubiquitinylation  (34) Signaling & Cell Circuits  (130) single cell sequencing  (3) Small Molecules in Development of Therapeutic Drugs  (71) Social Development  (15) Specialized 3D BioPrinters (Cornea  (1) Statistical Methods for Research Evaluation  (137) Stem Cells for Regenerative Medicine  (177)    Cardiac muscle regeneration  (19)    Competition in regenerative stem cell science  (18)    Human neural progenitor cells  (8)    Skeletal muscle regeneration  (9) STORM  (2) Stress Disorders  (19) Substance Abuse  (4) Systemic Inflammatory Response Related Disorders  (161)    Inflammatory Pathophysiology  (9) Technology Transfer: Biotech and Pharmaceutical  (354) therapeutics  (3) Tissue Engineering and Regenerative Medicine  (22) Tissue Microenvironment  (5) Transarterial Chemoembolization  (2) Transcriptomics  (47) Transformative Technologies in Healthcare  (23) Translational Science  (230)    Best evidence  (52)    Bias measurement tools  (2)    Evidence-based decision-making  (29)    Inferential analysis  (25)    Intra-rater error  (1)    Quality Assurance  (8)    Random Error  (2)    Systematic Error (Bias)  (6)    Total error  (2)    Translational Effectiveness  (49)    Translational Research  (92) Trends in Global Economy  (6) Uncategorized  (1,019) Unfolded Protein Response (UPR)  (6) US and Global Economy: Trends and Findings  (9) Venture Capital  (47)    Income Geographic Distribution  (3)    Institutional Capital Raised by Female Founders  (6) virology  (10) Vision  (7) Voices of Patients and Healthcare Providers  (22) Water Transporters  (8) Wearable Tech + Digital Health  (5) Anemia  (22) Neutropenia  (8) Neutrophilia  (9) Platelet count disorder  (9) Folate and B12  (7) Iron deficiency  (5) Myelodysplasia  (13) Myelofibrosis  (10)

• Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

• • 2012pharmaceutical
  • sjwilliamspa